Endogenous Anticoagulants

Topics in Companion Animal Medicine

Volumn 27, Issue 2, 2012, Pages 81-87

  Kubier, Amy ^a   O'Brien, Mauria ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Antithrombin; Coagulation; Protein C; Protein S; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL; ANIMAL DISEASE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CAT; CAT DISEASE; DOG; DOG DISEASE; HOMEOSTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; CAT DISEASES; CATS; DOG DISEASES; DOGS; HOMEOSTASIS; LIPOPROTEINS; PROTEIN C; PROTEIN S;

EID: 84867030040     PISSN: 19389736     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tcam.2012.07.003     Document Type: Review

References (129)

1. Kasthuri R.S., Glover S.L., Boles J., Mackman N. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost 2010, 36:764-771.
2. Smith S. The cell based model of coagulation. J Vet Emerg Crit Care 2009, 19:3-10.
3. Broze G.J., Warren L.A., Novotny W.F., Higuchi D.A., Girard J.J., Miletich J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988, 71:335-343.
4. McVey J.H. Tissue factor pathway. Baillieres Clin Haematol 1994, 7:469-484.
5. Novotny W.F., Brown S.G., Miletich J.P., Rader D.J., Broze G.J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991, 78:387-393.
6. Maroney S.A., Mast A.E. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci 2008, 38:9-14.
7. Novotny W.F., Girard T.J., Miletich J.P., Broze G.J. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989, 264:18832-18837.
8. Sandset P.M. Tissue factor pathway inhibitor (TFPI)-an update. Haemostasis 1996, 26(suppl 4):154-165.
9. Broze G.J. Tissue factor pathway inhibitor. Thromb Haemost 1995, 74:90-93.
10. Gomez K., McVey J.H., Tuddenham E. Inhibition of coagulation by macromolecular complexes. Haematologica 2005, 90:1570-1576.
11. Lupu C., Poulsen E., Roquefeuil S., Westmuckett A.D., Kakkar V.V., Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999, 19:2251-2262.
12. Lindahl A.K. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 1997, 33:286-291.
13. Hansen J.B., Svensson B., Olsen R., Ezban M., Osterud B., Paulssen R.H. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000, 83:937-943.
14. Ye Z., Takano R., Hayashi K., et al. Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction. Thromb Res 1998, 89:263-270.
15. Lindahl A.K., Sandset P.M., Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992, 3:439-449.
16. Hubbard A.R., Weller L.J., Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinolysis 1994, 5:819-823.
17. Kario K., Matsuo T., Yamada T., Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994, 71:275-279.
18. Leurs P.B., van Oerle R., Hamulyak K., Wolffenbuttel B.H. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995, 44:80-84.
19. Van Den Boogaard F.E., Brands X., Schultz M.J., et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011, 9:122-132.
20. Iversen N., Lindahl A.K., Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res 2002, 105:33-36.
21. Morishita E., Asakura H., Saito M., et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis 2001, 154:203-212.
22. Gando S., Kameue T., Morimoto Y., Matsuda N., Hayakawa M., Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002, 30:1729-1734.
23. Williams L., Tucker T.A., Koenig K., et al. Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice. Am J Respir Cell Mol Biol 2012, 46:173-179.
24. Zhang Q., Zhang Y., Wang S.Z., et al. Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. J Exp Clin Cancer Res 2012, 31:1.
25. Jia Y., Yang Y., Brock M.V., et al. Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics 2012, 4:135-146.
26. Stavik B., Skretting G., Aasheim H.C., et al. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer 2011, 11:357.
27. Dahm A., Van Hylckama Vlieg A., Bendz B., Rosendaal F., Bertina R.M., Sandset P.M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003, 101:4387-4392.
28. Berrettini M., Parise P., Ricotta S., Iorio A., Peirone C., Nenci C.G. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. Thromb Haemost 1996, 75:395-400.
29. Rapp J.H., Pan X.M., Ghermay A., Gazetas P., Brady S.E., Reilly L.M. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model. J Vasc Surg 1997, 25:726-729.
30. Ezzat W.H., Dahl J.P., Luginbuhl A., Gordin E., Krein H., Heffelfinger R.N. Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model. Laryngoscope 2010, 120:2172-2176.
31. van't Veer C., Hackeng T.M., Delahaye C., Sixma J.J., Bouma B.N. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994, 84:1132-1142.
32. Hakki S.I., Fareed J., Hoppensteadt D.A., et al. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. Clin Appl Thromb/Hemost 2001, 7:65-71.
33. Kijowski R., Hoppensteadt D., Walenga J., Borris L., Lassen M.R., Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Thromb Res 1994, 74:53-64.
34. Day K.C., Hoffman L.C., Palmier M.O., et al. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990, 76:1538-1545.
35. Creasey A.A., Chang A.C., Feigen L., Wn T.C., Taylor F.B., Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993, 91:2850-2860.
36. Camerota A.J., Creasey A.A., Patla V., Larkin V.A., Fink M.P. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 1998, 177:668-676.
37. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000, 28:S31-S33.
38. Abraham E., Reinhart K., Opal S., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.
39. Roemisch J., Gray E., Hoffmann J.N., Wiedermann C.J. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002, 13:657-670.
40. Damus P.S., Hicks M., Rosenberg R.D. Anticoagulant action of heparin. Nature 1973, 246:355-357.
41. Okajima K., Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998, 24:27-32.
42. Yamashiro K., Kiryu J., Tsujikawa A., et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2001, 42:1553-1560.
43. Justus A.C., Roussev R., Norcross J.L., Faulk W.P. Antithrombin binding by human umbilical vein endothelial cells: effects of exogenous heparin. Thromb Res 1995, 79:175-186.
44. Swedenborg J. The mechanisms of action of alpha- and beta-isoforms of antithrombin. Blood Coagul Fibrinolysis 1998, 9(suppl 3):S7-S10.
45. Stead N., Kaplan A.P., Rosenberg R.D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976, 251:6481-6488.
46. Rosenberg J.S., McKenna P.W., Rosenberg R.D. Inhibition of human factor IXa by human antithrombin. J Biol Chem 1975, 250:8883-8888.
47. Rao L.V., Nordfang O., Hoang A.D., Pendurthi U.R. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995, 85:121-129.
48. Opal S.M., Kessler C.M., Roemisch J., Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002, 30:S325-S331.
49. Olds R.J., Lane D.A., Mille B., Chowdhury V., Thein S.L. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Hemost 1994, 20:353-372.
50. Opal S.M. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000, 28:S34-S37.
51. Marcum J.A., Rosenberg R.D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984, 23:1730-1737.
52. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990, 16(suppl):12-18.
53. Handeland G.F., Abildgaard U., Holm H.A., Arnesen K.E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990, 39:107-112.
54. Young E., Wells P., Holloway S., Weitz J., Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994, 71:300-304.
55. Bjornsson T.D., Wolfram K.M., Kitchell B.B. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982, 31:104-113.
56. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
57. Gray E., Souter P., Roemisch J., Poole S. Antithrombin inhibits in vitro lipopolysaccharide induced procoagulant activity and cytokine production. Shock 2000, 13:147.
58. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Römisch J., Wiedermann C.J., Wiederman C.J. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 2002, 115:227-236.
59. Souter P.J., Thomas S., Hubbard A.R., Poole S., Römisch J., Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001, 29:134-139.
60. Coughlin S.R. Protease-activated receptors in vascular biology. Thromb Haemost 2001, 86:298-307.
61. Senden N.H., Jeunhomme T.M., Heemskerk J.W., et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998, 161:4318-4324.
62. Hoffmann J.N., Vollmar B., Inthorn D., Schildberg F.W., Menger M.D. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure. Shock 2000, 14:528-534.
63. Goodnight S.H., Schaeffer J.L., Sheth K. Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assays. Am J Clin Pathol 1980, 73:639-647.
64. Axelsson F. Antithrombin. Chromogenix 1995, 1-27. Chromogenix, Mölndal, Sweden.
65. Kuzi S., Segev G., Haruvi E., Aroch I. Plasma antithrombin activity as a diagnostic and prognostic indicator in dogs: a retrospective study of 149 dogs. J Vet Intern Med 2010, 24:587-596.
66. Donahue S., Brooks M., Otto C. Examination of hemostatic parameters to detect hypercoagulability in dogs with severe protein losing nephropathy. J Vet Emerg Crit Care 2011, 21:346-355.
67. Goodwin L.V., Goggs R., Chan D.L., Allenspach K. Hypercoagulability in dogs with protein-losing enteropathy. J Vet Intern Med 2011, 25:273-277.
68. Eralp O., Yilmaz Z., Failing K., Moritz A., Bauer N. Effect of experimental endotoxemia on thrombelastography parameters, secondary and tertiary hemostasis in dogs. J Vet Intern Med 2011, 25:524-531.
69. Sas G., Petö I., Bánhegyi D., Blaskó G., Domján G. Heterogeneity of the "classical" antithrombin III deficiency. Thromb Haemost 1980, 43:133-136.
70. Sas G. Hereditary antithrombin III deficiency: biochemical aspects. Haematologica (Budap) 1984, 17:81-86.
71. Maclean P.S., Tait R.C. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007, 67:1429-1440.
72. de Laforcade A.M., Rozanski E.A., Freeman L.M., Li W. Serial evaluation of protein C and antithrombin in dogs with sepsis. J Vet Intern Med 2008, 22:26-30.
73. Levi M., van der Poll T., Bller H.R. Bidirectional relation between inflammation and coagulation. Circulation 2004, 109:2698-2704.
74. Kobayashi M., Shimada K., Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990, 144:383-390.
75. Hagag A.A., Elmahdy H.S., Ezzat A.A. Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis. Indian Pediatr 2011, 48:471-473.
76. Iwako H., Tashiro H., Amano H., et al. Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol 31 March 2012, [epub ahead of print].
77. Egi M., Morimatsu H., Wiedermann C.J., et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb Haemost 2009, 101:696-705.
78. Zbanyszek M., Procajło A., Stopyra A., Sobiech P., Rajski K. The coagulation system in horses with colic. Pol J Vet Sci 2004, 7:53-58.
79. Darien B., Potema J., Moore J., Travis J. Antithrombin III activity in horses with colic: an analysis of 46 cases. Equine Vet J 1991, 23:211-214.
80. Opal S. Antithrombin II in the treatment of severe sepsis: the results of a phase II multicenter clinical trial. J Anesth Intensive Lung 2001, 25:273-277.
81. Warren B.L., Eid A., Singer P., et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
82. Knaub S., Keinecke J., Mescheder A., Heinrichs H. Antithrombin III in patients with severe sepsis-a clinical development plan. Ann Hematol 1998, 76:A47.
83. Sakr Y., Reinhart K., Hagel S., Kientopf M., Brunkhorst F. Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. Anesth Analg 2007, 105:715-723.
84. Eid A., Wiedermann C.J., Kinasewitz G.T. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. Anesth Analg 2008, 107:1633-1638.
85. Kienast J., Juers M., Wiedermann C.J., et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4:90-97.
86. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008, 2008(36):296-327.
87. Strickland D.K., Kessler C.M. Biochemical and functional properties of protein C and protein S. Clin Chim Acta 1987, 170:1-24.
88. Castellino F.J., Ploplis V.A. The protein C pathway and pathologic processes. J Thromb Haemost 2009, 7(suppl 1):140-145.
89. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981, 68:1370-1373.
90. Petäjä J., Fernández J.A., Gruber A., Griffin J.H. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest 1997, 99:2655-2663.
91. Foster D., Davie E.W. Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci U S A 1984, 81:4766-4770.
92. Esmon C.T., Esmon N.L., Harris K.W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982, 257:7944-7947.
93. Vehar G., Davie E. Preparation and properties of bovine factor VII (antihemophiliac factor). Biochemistry (Mosc) 1980, 19:401.
94. Riewald M., Petrovan R.J., Donner A., Mueller B.M., Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002, 296:1880-1882.
95. Kisiel W., Canfield W.M., Ericsson L.H., Davie E.W. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977, 16:5824-5831.
96. Taylor F.B., Lockhart M.S. A new function for activated protein C: activated protein C prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes-platelet suspensions stimulated by phorbol diester. Thromb Res 1985, 37:155-164.
97. Hickton C.M., Felding P., Ikeda K., Martinsson G., Nilsson I.M. A functional assay of protein C in human plasma. Thromb Res 1986, 41:501-508.
98. Fry M.M., Snyder K.R., Tobias K.M., Williamson B.G., Reed G.A. Protein C activity in dogs: adaptation of a commercial human colorimetric assay and evaluation of effects of storage time and temperature. Vet Med Int 2011, 751849.
99. Toulza O., Center S.A., Brooks M.B., Erb H.N., Warner K.L., Deal W. Evaluation of plasma protein C activity for detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet Med Assoc 2006, 229:1761-1771.
100. Bereczky Z., Kovács K.B., Muszbek L. Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med 2010, 48(suppl 1):S53-S66.
101. Kanji S., Devlin J.W., Piekos K.A., Racine E. Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Pharmacotherapy 2001, 21:1389-1402.
102. Prins M., Schellens C.J., van Leeuwen M.W., Rothuizen J., Teske E. Coagulation disorders in dogs with hepatic disease. Vet J 2010, 185:163-168.
103. Tarnow I., Falk T., Tidholm A., et al. Hemostatic biomarkers in dogs with chronic congestive heart failure. J Vet Intern Med 2007, 21:451-457.
104. Dereszynski D.M., Center S.A., Randolph J.F., et al. Clinical and clinicopathologic features of dogs that consumed foodborne hepatotoxic aflatoxins: 72 cases (2005-06). J Am Vet Med Assoc 2008, 232:1329-1337.
105. Scaldaferri F., Sans M., Vetrano S., et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007, 117:1951-1960.
106. Finigan J.H., Dudek S.M., Singleton P.A., et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005, 280:17286-17293.
107. Shibata M., Kumar S.R., Amar A., et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001, 103:1799-1805.
108. Isermann B., Vinnikov I.A., Madhusudhan T., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
109. Buisson-Legendre N., Smith S., March L., Jackson C. Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis Rheum 2004, 50:2151-2156.
110. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
111. Barie P.S. An opinion too far-the campaign against the Surviving Sepsis Campaign. Surg Infect (Larchmt) 2006, 7:485-488.
112. FDA Drug Safety Communication: voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit Accessed July 30, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm277114.htm.
113. Ranieri V.M., Thompson B.T., Barie P.S., et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064.
114. Marti-Carvajal A.J., Sola I., Lathyris D., Cardona A.F. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011, CD004388.
115. Marlar R.A., Gausman J.N. Protein S abnormalities: a diagnostic nightmare. Am J Hematol 2011, 86:418-421.
116. Mosnier L.O., Meijers J.C., Bouma B.N. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis. Thromb Haemost 2001, 86:1040-1046.
117. Peraramelli S., Rosing J., Hackeng T.M. TFPI-dependent activities of protein S. Thromb Res 2012, 129(suppl 2):S23-S26.
118. Castoldi E., Hackeng T.M. Regulation of coagulation by protein S. Curr Opin Hematol 2008, 15:529-536.
119. Hackeng T.M., Hessing M., van't Veer C., et al. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993, 268:3993-4000.
120. Dahlbäck B. The tale of protein S and C4b-binding protein, a story of affection. Thromb Haemost 2007, 98:90-96.
121. Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986, 261:12022-12027.
122. Van de Poel R.H., Meijers J.C., Bouma B.N. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost 2001, 85:761-765.
123. Comp P.C., Doray D., Patton D., Esmon C.T. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986, 67:504-508.
124. ten Kate M.K., van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia 2008, 14:1222-1228.
125. Rosing J., Maurissen L.F., Tchaikovski S.N., Tans G., Hackeng T.M. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res 2008, 122(suppl 1):S60-S63.
126. Pegelow C.H., Ledford M., Young J.N., Zilleruelo G. Severe protein S deficiency in a newborn. Pediatrics 1992, 89:674-676.
127. Comp P.C., Nixon R.R., Cooper M.R., Esmon C.T. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984, 74:2082-2088.
128. Vervloet M., Thijs L., CE H. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998, 24:33-44.
129. Lipe B., Ornstein D.L. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation 2011, 124:e365-e368.